Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discount will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Most Popular in Business
Genentech will pay Array BioPharma $28 million as part of a deal to jointly develop the companies’ small-molecule inhibitors of Checkpoint kinase 1 (ChK-1), a protein implicated in cancer cell survival. Included in the pact are Genentech’s GDC-0425, in Phase I studies, and Array’s ARRY-575, which has yet to be tested in humans. Array could gain up to $685 million in milestone payments along with royalties on any drug that is commercialized under the pact from either firm. ChK-1 helps a tumor cell to repair damaged DNA after exposure to chemotherapy; if the protein is blocked, chemotherapy should kill cancer cells more effectively.
This article has been sent to the following recipient: